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ABSTRACT
The Objective of this study was to assess possible association of history of migraine with pre-eclampsia (PE).
This was a retrospective study to compare history of migraine in 90 women affected by PE with 90 women
without PE as the control group. They recruited by a nonrandomized consecutive sampling method. Data
were collected by a questionnaire including demographic, medical, obstetrics, and migraine assessment sec-
tions. Data were analyzed using SPSS. Results showed an increased risk of PE in women with history of
migraine (odds ratio: 2.87; p < 0.05). Result demonstrated that migraine history in the case group is 14/4%
and in control group is 5/6%. Gestational age (GA) at delivery and weight of neonate (WN) were significantly
lower compared to control (GA: 37.3 ± 2.6 vs. 38.7± 1.3 weeks T test; P < 0.01) (WN: 2930 ± 690 vs. 3330 ± 420;
T test; P < 0.0). Cesarean section was more frequent in the PE group compared to the control group [37 (42%)
vs. 14 (15.6%)]; chi square; p < 0.01]. The association of migraine with PE is the result of some similar mecha-
nism leading to endothelial dysfunction. Frequent reports of an association between migraine and PE in differ-
ent populations suggest a history of migraine as a risk factor for PE/gestational hypertension (GH).
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INTRODUCTION
Hypertensive disorders of pregnancy with the overall
incidence of 5.9% (1) remains the leading cause of
direct maternal deaths in many countries (2,3). Pre-
eclampsia (PE) is demonstrated to be a major cause of
poor outcome in pregnancy. It is associated with fetal
growth restriction, low birth weight, preterm delivery,
respiratory distress syndrome, and admission to neona-
tal intensive care, diminished amniotic fluid, and altered
oxygenation (4–6). Hypertensive disorders of pregnancy
are classified as PE, eclampsia, gestational hypertension
(GH), chronic hypertension, and PE superimposed on
chronic hypertension (7). Pre-eclampsia occurs after
midgestation, is defined by the de novo appearance of
hypertension (systolic blood pressure (SBP) of ≥140 mm
Hg or diastolic blood pressure (DBP) of ≥ 90 mm Hg),
accompanied by a new of onset proteinuria, and defined
as ≥ 300 mg per 24 h.
Pre-eclampsia is a multisystem disorder, unique to
pregnancy (8). The mechanisms responsible for the
pathogenesis of PE are poorly understood. It is sup-
posed to be determined by two essential processes—
the first given by a superficial trophoblastic invasion
and a poor remodeling of the spiral arteries and the
maternal deciduas (9). Alterations in endothelial cell
function by activating agents produced by the placenta
are proposed to initiate the clinical syndromes of PE.
Circulating factors, such as inflammatory cytokines,
are shown to be elevated in pre-eclamptic women and
are proposed to be important links between placental
ischemia and endothelial dysfunction (10).
Migraine is a chronic, often-inherited condition
involving brain hypersensitivity and a lowered thresh-
old for trigeminal-vascular activation (11) results in a
marked decrease in a patient’s quality of life (12).
Migraine can be divided into two major subtypes: 1)
migraine without aura and 2) migraine with aura (13).
The prevalence of migraine was 17.1% in women and
5.6% in men Migraine is one of the most common
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neurological disorders in adult women (14) which
means a female/male prevalence ratio of 3:1. This
prevalence rises from 4% before puberty to a peak of
25% in women during their child-bearing years with a
decrease after menopause (15,16).
The pathophysiology of migraine headaches is not
clearly understood. Growing evidence supports the role
of neurogenic peptides, such as serotonin and dopamine,
in the brain. These vasoactive neuropeptides stimulate an
inflammatory cascade with the release of endothelial
cells, mast cells, and platelets. This inflammation causes
vasodilation and a perivascular reaction (17).
Association of migraine with PE has been assessed
from 1954. This cross-sectional study showed that
21.4% of migraneous pregnant women develop tox-
emia (18). However, the next case-control study
showed no difference between women in migraneous
and control groups reporting a history of toxemia (19).
One subsequent cohort study (20) and another case
control study (21) showed that women with migraine
have higher chance of developing PE.
In addition, a history of migraine was associated
with an increased risk of PE in pregnant women (22–26).
Adeny and Williams (27) reviewed 10 studies address-
ing the association between migraine and PE and/or
GH. Of the 10 studies, 8 reported a positive associa-
tion. They recommend more rigorous studies to clarify
the relationship. Although most of these studies
showed a positive association between migraine and
PE, the criteria to diagnosis and classification of PE
and migraine was extensively different. Allias et al. (28)
discussed migraine as a risk factor in pregnancy and
suggest further research to assess the existence and
extent of the risks posed by migraine during pregnancy.
This study aims to assess the association between
migraine and PE, using conventional rigorous criteria
for diagnosis and classification of PE and migraine in
an Iranian population.
MATERIAL AND METHODS
This was a retrospective case control study of 180
women in two groups of 90, in the post-partum unit of
Kashan University hospitals. They subjects have only a
single fetus and should have no history of chronic
hypertension or other medical diseases. They should
have at least eight prenatal visits during pregnancy
with two visits occurring before the 20th week of preg-
nancy. The patients should have no report of hyperten-
sion in their PNC care visits before the 20th week of
pregnancy. They were recruited for the study if they
met this inclusion criteria for the study, and if following
an explanation about the study, they gave us written
consent. The Ethical Committee of Shahid Beheshti
Medical Science University and Kashan Medical
Science University confirmed the study.
With a convenience sampling method, 90 women
with recorded PE (cases group) were recruited in post-
partum units of two Kashan University Hospitals. The
criteria to diagnose and classification of PE was based
on the Report of the National High Blood Pressure
Education Program Working Group on high blood
pressure in pregnancy (29). Based on the NHBPEP
Report, PE is a pregnancy-specific syndrome that usu-
ally occurs after 20 weeks of gestation. It presents as de
novo hypertension (SBP of ≥ 140 mmHg and/or DBP
of ≥ 90 mmHg) on two occasions, 6 h apart, accom-
panied by a new onset of proteinuria defined as ≥
300 mg/24 h (29, 30).
Criteria for the diagnosis of migraine was a pro-
vided questionnaire based on the Headache Interna-
tional Association (13) (Figure 1). If the subjects were
diagnosed as migraneous based on ICHD-II, they
were referred to the neurologist for further assessment
and the final confirmation of migraine. Women with
migraine were also asked about the average number of
migraines in a month, their age of migraine initiation,
duration and intensity of headaches, and migraine
occurrence in menstruation. The tool for data collection
consisted of three sections of a demographic question-
naire, a checklist to assess hypertension, and a checklist
to assess migraine. Content validity and test-retest was
performed to assess validity and reliability of the ques-
tionnaires. Data was analyzed by SPSS 13 (SPSS Inc.,
Chicago, IL) using T-test, chi-square, Mann-Withney,
and odds ratio with 95% confidence interval.
RESULTS
One hundred eighty women aged 27.48 ± 5.4 (mean ±
SD) participated in the study. They participated in
two groups of 90 women in each PE (case) group and
without PE (control) group. Their demographic and
fertility characteristics are compared and summarized
in Table 1. The comparison between the two groups
of case and control regarding the possible confounding
variables, demonstrated no significant differences
between them (Table 1).
Six women (6.7%) in the control group and 9
women (10%) in the case group had a history of PE
during previous pregnancies which was not signifi-
cantly different between the two groups (chi-square;
p > 0.05). The remaining subjects were primiparous
women or women without a history of GH or PE dur-
ing their last pregnancy. In addition, 26 women
(28.9%) of in the case group and 23 women (25.6%)
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in the control group had a family history of hyperten-
sion which also was not significantly different between
the two groups (chi-square; p > 0.05). Eighteen (10%)
women were affected by migraine and there were no
cases of migraine with aura.
There was a significant difference between the two
groups regarding their gestational age at the time of
delivery, the weight of their neonate, and the method
of their delivery (Table 2).
The comparison between the two groups demon-
strated a significant difference in their history of
migraine (chi-square; P < 0.05). The odds ratio (OR)
estimated that there is 2.87 times more history of
migraine among the PE group vs. the control group
(upper and lower limit of 2.33 and 3.1, respecticely;
confidence interval (CI): 95%) (Table 3).
DISCUSSION
This is the first report of an association between
migraine and PE in an Asian country. Our findings are
consistent with previous reports showing a clear asso-
ciation between migraine and PE and we have
extended it to the Iranian population. We used the
conventional rigorous NHBPEP (30) criteria for diag-
nosis and classification of PE as well as ICHD-II (13)
criteria for the diagnosis and classification of migraine
plus further confirmation of migraine by the neurolo-
gist, while most of the previous studies relied on the
diagnosis of migraine based on the patients self-report.
The correlation between migraine and an increased
risk of PE is attributed to some similarities in patho-
physiology of these disorders. The mechanism of
migraine and PE are not clearly understood but abnor-
mal reactivity of vascular endothelial cells and the
inflammatory release of similar cascades of mediators
such as cytokines are believed to cause this association.
Abnormal release of cytokines and endothelins are
reported in both migraine and PE.
Nitric oxide, oxidative stress, endothelin, arachi-
donic acid metabolites, renin-angiotensin system,
cytokines, angiogenic factors, and metabolic and
dietary factors are described as the potential mediators
of endothelial dysfunction in PE (31). It is postulated
that inadequate remodeling of the uterine spiral arter-
ies in PE leads to focal ischemia and the generation of
inflammatory cytokines, such as tumor necrosis factor
(TNF alpha) and interleukins (ILs), by the placenta
and anything additional (32). Increased levels of IL-6
and IL-8 (33) and elevated levels of TNF-alpha and
IL-6 (34) may contribute to the putative endothelial
dysfunction of PE. Migraine is also a neurovascular
disorder involving cortical depression, neurogenic
inflammation, and vasodilation. Various neuropeptides
and cytokines have been implicated in the pathophysi-
ology of migraine including calcitonin gene-related
peptide, interleukin (IL)-1, IL-6, and tumour necrosis
factor (TNF)-alpha (35).
Women with severe PE have a higher median
plasma concentration of adiponectin than that of nor-
mal pregnant women (36). It is supposed that adi-
ponectin levels are potentially altered during migraine
attacks. The anti-inflammatory activities of adiponectin
FIGURE 1 The International Classification of Headache
Disorders II (ICHD-II) criteria for migraine without aura (13).
Diagnostic Criteria for
Migraine Without Aura
A. At least five headache attacks
fulfilling criteria B through D
B. Headache attacks lasting
4 to 72 hours (untreated or
unsuccessfully treated)
C. Headache has at least two of
the following characteristics:
D. During headache, at least one
of the following characteristics:
E. Headache cannot be
attributed to another disorder
Unilateral location
Pulsating quality
Moderate or severe pain
intensity
Aggravation by, or causing
avoidance of, routine physical
activity (eg, walking or climbing
stairs)
Nausea and/or vomiting
Photophobia and/or
phonophobia
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include inhibition of IL-6 and TNF-induced IL-8 for-
mation, as well as induction of the anti-inflammatory
cytokines IL-10 and IL-1 receptor antagonist. (35).
Pre-eclampsia is associated with higher circulating
and placental endothelin-1 levels, observation that
explains, at least in part, vasoconstriction and oxida-
tive stress (37). Endothelins may be the mediators of the
vasoconstrictive phase in migraine attacks as well (38).
The rennin-angiotensin system (RAS) is involved in
the development of PE, and the presence of the angio-
tensin II, type I receptor agonistic auto-antibody are
frequently reported (39,10). Angiotensin-converting
enzyme inhibitors and angiotensin II receptor blockers
also demonstrate to be effective in the prophylactic
TABLE 1 The comparison of individual and fertility characteristics of women with PE (the case group) and women
without it (the control group) in Kashan hospitals 2007
Group
Characteristics Case N = 90 Control N = 90 Statistical Test
Individual
Age (years); mean ± SD 27.3 ± 5.9 27.66 ± 5.2 T test; p > 0.05
BMI; mean ± SD 28 ± 5.6 26.5 ± 4.6 T test; p > 0.05
Occupation N (%)
Housewife 87 (96.7) 87 (96.7) chi square; p > 0.05
Employed 3 (3.3) 3 (3.3)
Fertility
Gravida; mean ± SD 2.09 ± 1.3 2.09 ± 1.3 T test; p > 0.05
Parity; mean ± SD 1.8 ± 1.9 1.88 ± 0.9 T test; p > 0.05
Abortion; mean ± SD 0.5 ± 0.2 0.5 ± 0.2 T test; p > 0.05
Unwanted pregnancy; N (%) 19 (21.1) 22 (24.4) chi square; p > 0.05
Birth space (years); mean ± SD 3.8 ± 4.8 3.9 ± 4.9 Mann-Withney, p > 0.05
Gender of neonate; N (%)
female 40 (44.4) 43 (47.8)
chi square; p > 0.05
male 50 (55.6) 57 (52.2)
Oral contraceptive use; N (%) 15 (16.7) 17 (18.9) chi square; p > 0.05
TABLE 2 The comparison of gestational age at the time of delivery (GA), method of delivery, and weight of neonate of
women with PE (case group) and women without it (control group) in Kashan hospitals 2007
Group
Case N = 90 Control N = 90 Statistical TestCharacteristics
Gestational age at birth (weeks); mean ± SD 37.3 ± 2.6 38.7 ± 1.3 T test; P < 0.01
Method of delivery; N (%)
Normal vaginal 53 (58) 76 (84.4) chi square; p < 0.01
Cesarean 37 (42) 14 (15.6)
Weight of neonate; mean ± SD 2930 ± 690 3330 ± 420 T test; P < 0.01
TABLE 3 The comparison of history of migraine of women
with PE (case group) and women without it (control group) in
Kashan hospitals 2007
Group
Case 
N = 90
Control 
N = 90 Statistical TestCharacteristics
History of migraine 13 (14.4) 5 (5.6) chi square; 
P < 0.05
No history of migraine 77 (85.6) 85 (94.4) odds ratio: 2.87; 
p < 0.05
Total 90 (100) 90 (100)
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treatment of migraine and it is likely that the RAS has
a clinically important role in migraine pathophysiology
as well (40).
Platelet sensitivity to prostaglandin E1 inhibition is
reduced in PE (41) and platelet insensitivity to pros-
taglandin E1 was also reported in migraine (42).
Melatonin was demonstrated to be involved in
endothelial dysfunction of both migraine and PE. The
antioxidative effect of melatonin on the oxidized low-
density lipoprotein induced impairment of nitric oxide
production in human umbilical artery, which is a cause
of endothelial dysfunction in PE (43). Altered melato-
nin levels in cluster headaches and migraines have also
been documented. Melatonin mechanisms are related
to headache pathophysiology in many ways, including
its anti-inflammatory effect, toxic-free radical scaveng-
ing, reduction of pro-inflammatory cytokine upregula-
tion, and nitric oxide synthase activity (44).
Migraine and PE occurrence are both influenced by
sex hormones (14,45). The greater incidence of hyper-
tension in men and post-menopausal women compared
to premenopausal women has suggested sex hormone
differences in vascular function. Activation of sex hor-
mone receptors on the plasma membrane stimulates
endothelium-dependent vascular relaxation. Sex hor-
mones also cause endothelium-independent inhibition of
vascular smooth muscle contraction (46). Estrogen
increases endothelial vasodilator function, promotes
angiogenesis, and modulates autonomic function (47).
Migraine is also three times more common in post-
pubertal women than in men. Migraine is frequently
exacerbated perimenstrually and commonly occurs
exclusively at that time (48). It is often benefited by
pregnancy and menopause. These improvements have
been attributed to the absence of hormone fluctuations.
Estrogen withdrawal has been implicated as a mecha-
nism for triggering migraines (49, 14). It has been estab-
lished that estrogen decreases cerebral vascular tone and
increases cerebral blood flow by enhancing endothelial-
derived nitric oxide and prostacyclin pathways (50).
Cerebrovascular inflammation is suppressed by
estrogen but increased by progesterone. Evidence sug-
gests that sex steroids also modulate blood-brain bar-
rier permeability. Estrogen has important protective
effects on cerebral endothelial cells by increasing mito-
chondrial efficiency, decreasing free radical produc-
tion, promoting cell survival and stimulating
angiogenesis (51). Female sex steroids have an impor-
tant role in the pathology of migraines by modulating
several mediators and/or receptor systems (52).
The results of our study showed that the gestational
age at delivery and the neonatal weight of pre-eclamptic
group is significantly lower than the control group. In
some pre-eclamptic women, the termination of preg-
nancy is the only available option to prevent further
deterioration of the fetus and mother. Fifteen percent of
all preterm births are indicated early deliveries for PE
(53). In our study, the pre-eclamptic women had a higher
rate of cesarean section compared to the control group.
Indeed, patients with PE and those delivering small-
for-gestational age (SGA) neonates have higher plasma
concentrations of soluble vascular endothelial growth
factor receptor-1 (sVEGFR-1) and the soluble form of
endoglin (s-Eng), as well as lower plasma concentra-
tions of vascular endothelial growth factor (VEGF) and
placental growth factor (PlGF) than do patients with
normal pregnancies. Otherwise, an imbalance between
angiogenic and anti-angiogenic factors has been pro-
posed as central to the pathophysiology of PE (54).
Studies showed similar management for migraine
and PE. Asprin as an antiplatelet agents for preventing
and treating pre-eclampsia (55) and migraine (56).
Magnesium sulfate is the drug of choice to prevent and
treat eclampsia (57) and has prophylactic effects on
migraines (58).
Several population-based studies have linked
migraine and PE, with an increased risk of any
ischemic vascular events, including coronary heart dis-
ease and ischemic stroke.
Increasing evidence indicates that hypertension in
pregnancy is a risk factor for cardiovascular disease
(59) and stroke (60). Migraine with aura is associated
with an increased risk of ischaemic stroke, angina, and
other ischaemic vascular events, including myocardial
infarction (61). Potential mechanisms involve shared
risk factors, interrelationships between vascular
pathologies with migraine (11) and with PE (60).
Migraine has been questioned as one of the risk fac-
tors for pre-eclamsia (28). Although most epidemio-
logical studies demonstrate that women suffering from
migraines note a significant improvement of their
headaches during pregnancy (27.28), frequent reports
of a significant association between migraines and PE/
GH suggest a history of migraine as a risk factor for
PE. It seems that it is time to add a history of migraine
to the list of PE risk factors.
It should also be considered that case–control stud-
ies are overinvolved by recall bias and also by the fact
that headaches are often symptoms of PE and so the
PE group may reinforce headache history better than
the control group. Further research is necessary to
clarify the pathophysiology of both disorders—PE and
migraines
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